European Commission Approves KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First PD-1 Inhibitor Plus Antibody-Drug Conjugate Regimen for Adults With Cisplatin-Ineligible Resect
Go back to European Commission Approves KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First PD-1 Inhibitor Plus Antibody-Drug Conjugate Regimen for Adults With Cisplatin-Ineligible Resect| Merck & Co. (NYSE: MRK) | Delayed: 146.87 -0.28 (0.19%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $147.15 | 52 Week High | $65.46 | |||
| Open | $147.08 | 52 Week Low | $47.97 | |||
| Day High | $147.84 | P/E | 99.91 | |||
| Day Low | $145.74 | EPS | $1.47 | |||
| Volume | 31,159,364 | |||||
